ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0153

Patient Experience and Implementation of an Electronic Patient-Reported Outcome Measures (ePROM) System for Remote Monitoring in BIOBADASER

Isabel Castrejón Fernández1, Lucia Otero2, Antonio Mera-Valera3, Alicia Garcia4, Silvia Gomez-Sabater5, Raquel Martín-Domenech6, Jose Alvaro-Gracia7, Juan Camilo Sarmiento-Monroy8, Beatriz Ventosa2 and Fernando Sánchez-Alonso9, 1Department of Rheumatology. Hospital General Universitario Gregorio Marañon. IiSGM. Universidad Complutense Madrid, Madrid, Spain, 2Spanish Society of Rheumatology, Madrid, Spain, 3H. Clínico Universitario de Santiago, Santiago de Compostela, 4Rheumatologist, La Laguna, Spain, 5Rheumatology Department, Dr. Balmis General University Hospital, Alicante, Spain., Alicante, Spain, 6H. Universitario de Elda, Elda, Spain, 7Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Department of Rheumatology, Hospital General Universitario Gregorio Marañón and Faculty of Medicine, Complutense University of Madrid, Madrid, Spain, 8Hospital Clínic Barcelona, Barcelona, Spain, 9Sociedad Española de Reumatología, Madrid, Spain

Meeting: ACR Convergence 2025

Keywords: Biologicals, Patient reported outcomes, registry

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0145–0174) Epidemiology & Public Health Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Patient-Reported Outcome Measures (PROMs) are integral to shared decision-making and quality improvement in rheumatology. They are recommended for monitoring treatment response, assessing quality of life, and supporting clinical care. Scientific societies as EULAR have promoted standardized of PROM collection through data set recommendations and an Outcome Measures Library with instruments and validation data https://oml.eular.org/. This study aimed to: (1) develop and implement an electronic PROM (ePROM) system within BIOBADASER, a multicenter registry of advanced therapies; (2) analyze initial results post-implementation; and (3) evaluate usability and patient satisfaction.

Methods: A core set of validated and feasible PROMs was selected based on the International Consortium for Health Outcomes Measurement (ICHOM) recommendations and expert consensus. These were incorporated into a web-based application designed for patient self-completion via internet-enabled devices (smartphone, tablet, computer). Patients initiating advanced therapies were invited to participate. A pilot phase involving six centres was conducted from December 2023 to June 2024, followed by full-scale implementation across all centres. Descriptive statistics summarized demographic, clinical, and PROM data.

Results: From December 2023 to November 2024, 136 patients were invited to participate; 95 (70%) accessed the system, and 81 (60%) completed the questionnaires. Participants were predominantly female (64.2%) with a mean age of 50.9 years. The most common diagnoses were rheumatoid arthritis (35.8%), spondyloarthritis (19.8%), and psoriatic arthritis (17.3%). TNF inhibitors were the most frequently initiated therapy (72.8%). RAPID3 scores indicated high disease activity (mean 13.3 ± 6.8). Most patients reported minimal problems with mobility (69.1%), self-care (82.7%), usual activities (59.2%), and anxiety/depression (67.9%). The mean global health score was 55.6. Regarding usability, 81% experienced no or slight difficulty using the system, 79% found the instructions clear or very clear, and 80.2% were quite or very satisfied. A majority (66.7%) preferred online reporting over paper-based methods, and 87.6% felt comfortable using digital devices.

Conclusion: The ePROM system was feasible, well accepted, and effective for remote disease monitoring. Patients expressed high satisfaction and a preference for digital tools, supporting the integration of ePROMs into rheumatology registries to enhance personalized, patient-centred care.

Supporting image 1

Supporting image 2


Disclosures: I. Castrejón Fernández: None; L. Otero: None; A. Mera-Valera: None; A. Garcia: None; S. Gomez-Sabater: None; R. Martín-Domenech: None; J. Alvaro-Gracia: AbbVie/Abbott, 2, 6, AstraZeneca, 2, 6, Bristol-Myers Squibb(BMS), 2, 6, Galapagos, 2, 6, GlaxoSmithKlein(GSK), 2, 6, Novartis, 2, 6, Pfizer, 2, 6, UCB, 2, 6; J. Sarmiento-Monroy: AstraZeneca, 6, GlaxoSmithKlein(GSK), 6, Janssen, 6; B. Ventosa: None; F. Sánchez-Alonso: None.

To cite this abstract in AMA style:

Castrejón Fernández I, Otero L, Mera-Valera A, Garcia A, Gomez-Sabater S, Martín-Domenech R, Alvaro-Gracia J, Sarmiento-Monroy J, Ventosa B, Sánchez-Alonso F. Patient Experience and Implementation of an Electronic Patient-Reported Outcome Measures (ePROM) System for Remote Monitoring in BIOBADASER [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/patient-experience-and-implementation-of-an-electronic-patient-reported-outcome-measures-eprom-system-for-remote-monitoring-in-biobadaser/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patient-experience-and-implementation-of-an-electronic-patient-reported-outcome-measures-eprom-system-for-remote-monitoring-in-biobadaser/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology